Loading cancer entity…
Loading cancer entity…
Clinical trials
4,036 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (701)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02768792 | High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML | completed | Phase 2 | 38 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT04570709 | RN-Led Palliative and Supportive Care Intervention | completed | N/A | 67 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT04081753 | Remote Outpatient Temperature Monitoring for Early Detection of Febrile Neutropenia After Chemotherapy(REMEDY) | completed | N/A | 12 | Augusta UniversityOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT01838395 | Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients | completed | Phase 2 | 42 | BioLineRx, Ltd.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT02484391 | CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma | completed | Phase 1 | 48 | Wake Forest University Health SciencesOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03003325 | The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV(Low-PV) | completed | Phase 2 | 127 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04017546 | CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS | completed | Phase 1 | 14 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04500587 | Phase 1 First in Human Study of ZN-d5 as a Single Agent | completed | Phase 1 | 39 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.INDUSTRY | 7 | Sep 19, 2024 | clinicaltrials |
| NCT04827069 | A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML) | completed | Phase 1 | 75 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04267081 | Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening(VenEx) | completed | Phase 2 | 104 | Helsinki University Central HospitalOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT02920008 | Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia | completed | Phase 3 | 302 | Astex Pharmaceuticals, Inc.INDUSTRY | 15 | Aug 28, 2024 | clinicaltrials |
| NCT02096055 | Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT03306264 | Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML | completed | Phase 3 | 227 | Astex Pharmaceuticals, Inc.INDUSTRY | 10 | Aug 27, 2024 | clinicaltrials |
| NCT02326311 | Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response | completed | Phase 3 | 229 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT03372291 | Psychological Intervention Mobile App for Patients With AML | completed | N/A | 60 | Massachusetts General HospitalOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05326516 | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | completed | Phase 1 | 30 | Syndax PharmaceuticalsINDUSTRY | 2 | Aug 13, 2024 | clinicaltrials |
| NCT03275636 | Haploidentical Donor vs mMUD in Hematological Malignancies(HAMLET) | completed | Phase 2 / Phase 3 | 98 | DKMS gemeinnützige GmbHOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT02001818 | Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia(PInNACLe) | completed | Phase 2 | 60 | Australasian Leukaemia and Lymphoma GroupOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT02668653 | Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)(QuANTUM-First) | completed | Phase 3 | 539 | Daiichi SankyoINDUSTRY | 28 | Aug 6, 2024 | clinicaltrials |
| NCT00042003 | Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec) | completed | Phase 2 | 40 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 2, 2024 | clinicaltrials |
| NCT03813186 | Effect of Food on Blood Levels of ASTX727 | completed | Phase 1 | 18 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT02113982 | Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 138 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Aug 1, 2024 | clinicaltrials |
| NCT02323022 | Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 3 | 618 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT03902665 | Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75 | completed | Phase 2 | 19 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06516029 | Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib | completed | — | 111 | NovartisINDUSTRY | 1 | Jul 23, 2024 | clinicaltrials |
| NCT04901416 | Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS | completed | Phase 1 | 8 | Coeptis TherapeuticsINDUSTRY | 1 | Jul 19, 2024 | clinicaltrials |
| NCT06134102 | Clinical and Laboratory Characteristics of Polycythemia Vera(PV-ARC) | completed | — | 1,150 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT02626715 | Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS | completed | Phase 2 | 21 | Randy WindreichOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT02400281 | Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients | completed | Phase 1 / Phase 2 | 28 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04969601 | Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings(PACIFIC) | completed | Phase 1 / Phase 2 | 76 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT04835519 | Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 5 | Beijing Boren HospitalOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06463639 | FLT3 Clonal Evolution in Patients With Acute Myeloid Leukemia | completed | — | 1,213 | National Taiwan University HospitalOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT04629443 | Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia | completed | Phase 1 / Phase 2 | 17 | Institut de Recherches Internationales ServierOTHER | 4 | Jun 6, 2024 | clinicaltrials |
| NCT00590187 | Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients | completed | Phase 2 | 105 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 4, 2024 | clinicaltrials |
| NCT04580121 | A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. | completed | Phase 1 | 59 | Hoffmann-La RocheINDUSTRY | 10 | Jun 3, 2024 | clinicaltrials |
| NCT04243122 | Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients(AIRPORT-MPN) | completed | Phase 2 | 44 | Ottawa Hospital Research InstituteOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT03493646 | Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 | completed | Phase 2 | 40 | Kirby InstituteOTHER_GOV | 1 | May 28, 2024 | clinicaltrials |
| NCT06429670 | Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory(VENAURA) | completed | — | 500 | Hospices Civils de LyonOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT01995578 | Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse | completed | Phase 2 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT03333005 | Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and Neutropenia | completed | Phase 1 | 20 | Basilea PharmaceuticaINDUSTRY | 1 | May 17, 2024 | clinicaltrials |
| NCT03678493 | A Study of FMT in Patients With AML Allo HSCT in Recipients | completed | Phase 2 | 100 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT03047993 | Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT05988047 | Analysis of CMTM6 Expression in Patients With Acute Myeloid Leukemia | completed | — | 150 | University of FreiburgOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT04942730 | Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)(FluBuBe) | completed | Phase 2 | 50 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT05853445 | A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera(PAVE) | completed | — | 467 | Novartis PharmaceuticalsINDUSTRY | 1 | May 6, 2024 | clinicaltrials |
| NCT01597219 | Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers(UK-Haplo) | completed | Phase 2 | 77 | University College, LondonOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT03426605 | A Study of LAM-003 in Patients With Acute Myeloid Leukemia | completed | Phase 1 | 17 | OrphAI TherapeuticsINDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT05433532 | Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients | completed | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT02981914 | Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation | completed | Early Phase 1 | 12 | University of ChicagoOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT01751997 | Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors | completed | Phase 2 / Phase 3 | 116 | Byung-Sik ChoOTHER | 1 | Apr 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Sep 25, 2024source: clinicaltrials